This page shows the latest Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.
Oncology Newco will be established as an independent organisation and will be led by bluebird bio’s current chief executive officer Nick Leschly. ... It will also retain research and development responsibilities for bluebird’s oncology pipeline of
Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications. ... Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
This isn't just the CDCN's fight or my fight. It's Our Fight. ... The disorder is just as serious and life-threatening as many rare blood cancers, including progressive non-Hodgkin’s lymphoma.
Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and three solid tumours – colorectal, ovarian and bladder cancer. ... a run of M&A that hit a peak in 2017 with Gilead’s $11.9bn acquisition
New ‘chemotherapy-free’ treatment for patients with limited options. Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication ... lymphoma.
MCL is an aggressive type of non-Hodgkin’s lymphoma, and although it responds well to initial treatment, it eventually stops responding and the cancer cells continue to multiply. ... Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene
More from news
Approximately 19 fully matching, plus 152 partially matching documents found.
One of the best known pharma leaders in China, Dr Wu’s most recent achievement was to build Pfizer into one of the top multinational firms in China. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s
Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,
The significance of this lays in the evolving nature of Takeda's portfolio. ... Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Previously worked in oncology for Allos, Cephalon and AstraZeneca. Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...